Experimental models of Huntington's disease

被引:9
|
作者
Garcia-Ramos, R.
del Val-Fernandez, J.
Catalan-Alonso, M. J.
Barcia-Albacar, J. A.
Matias-Guiu, J.
机构
[1] Hosp Clin San Carlos, Unidad Trastornos Movimiento, E-28040 Madrid, Spain
[2] Hosp Clin San Carlos, Serv Neurocirugia, E-28040 Madrid, Spain
[3] Hosp Clin San Carlos, Inst Neurociencias, E-28040 Madrid, Spain
关键词
3-nitropropionic acid; cellular models; excitotoxic models; Huntington's disease; quinolinic acid; Transgenic mice;
D O I
10.33588/rn.4507.2007238
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Huntington's disease (HD) is an autosomal dominant hereditary disease caused by triplet repetition in exon I of the huntingtin protein located in chromosome 4. Medium spiny neurons in the striatum are selectively affected. Clinical manifestations include progressive behavioural, motor and cognitive disorders. There is no treatment available today capable of modifying the natural course of the disease. A great amount of research work is being carried out, much of which involves animal models of the disease. Development. We reviewed the articles published in PubMed on basic research into HD and analysed the most frequently used models. Transgenic mouse models, excitotoxic models, transgenic fly models and cell cultures are all used in studies into HD. The advantages and disadvantages of each of them are highlighted. Conclusion. The contribution made by each model of HD must be known in order to draw up a correct design in experimental studies of the disease. [REV NEUROL 2007; 45: 437-41]
引用
收藏
页码:437 / 441
页数:5
相关论文
共 50 条
  • [1] Citicoline is not protective in experimental models of Huntington's disease
    Mievis, Stephane
    Levivier, Marc
    Vassart, Gilbert
    Brotchi, Jacques
    Ledent, Catherine
    Blum, David
    NEUROBIOLOGY OF AGING, 2007, 28 (12) : 1944 - 1946
  • [2] Huntington's disease and mitochondrial alterations: emphasis on experimental models
    Perez-De la Cruz, Veronica
    Carrillo-Mora, Paul
    Santamaria, Abel
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2010, 42 (03) : 207 - 215
  • [3] Animal models of Huntington's disease
    Ramaswamy, Shilpa
    McBride, Jodi L.
    Kordower, Jeffrey H.
    ILAR JOURNAL, 2007, 48 (04) : 356 - 373
  • [4] Huntington’s disease and mitochondrial alterations: emphasis on experimental models
    Verónica Pérez-De la Cruz
    Paul Carrillo-Mora
    Abel Santamaría
    Journal of Bioenergetics and Biomembranes, 2010, 42 : 207 - 215
  • [5] Minocycline in phenotypic models of Huntington's disease
    Bantubungi, K
    Jacquard, C
    Greco, A
    Pintor, A
    Chtarto, A
    Tai, K
    Galas, MC
    Tenenbaum, L
    Déglon, N
    Popoli, P
    Minghetti, L
    Brouillet, E
    Brotchi, J
    Levivier, M
    Scbiffmann, SN
    Blum, D
    NEUROBIOLOGY OF DISEASE, 2005, 18 (01) : 206 - 217
  • [6] Huntington's disease: pathogenesis to animal models
    Kumar, Puneet
    Kalonia, Harikesh
    Kumar, Anil
    PHARMACOLOGICAL REPORTS, 2010, 62 (01) : 1 - 14
  • [7] Rodent Models of Huntington's Disease: An Overview
    Nittari, Giulio
    Roy, Proshanta
    Martinelli, Ilenia
    Bellitto, Vincenzo
    Tomassoni, Daniele
    Traini, Enea
    Tayebati, Seyed Khosrow
    Amenta, Francesco
    BIOMEDICINES, 2023, 11 (12)
  • [8] Neuroprotective Effects of Phytocannabinoid-Based Medicines in Experimental Models of Huntington's Disease
    Sagredo, Onintza
    Pazos, M. Ruth
    Satta, Valentina
    Ramos, Jose A.
    Pertwee, Roger G.
    Fernandez-Ruiz, Javier
    JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (09) : 1509 - 1518
  • [9] Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
    Bates, GP
    Hockly, E
    CURRENT OPINION IN NEUROLOGY, 2003, 16 (04) : 465 - 470
  • [10] Transgenic models of Huntington's disease
    Sathasivam, K
    Hobbs, C
    Mangiarini, L
    Mahal, A
    Turmaine, M
    Doherty, P
    Davies, SW
    Bates, GP
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1999, 354 (1386) : 963 - 969